INSP:NYE-Inspire Medical Systems Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 189.09

Change

+2.80 (+1.50)%

Market Cap

USD 5.63B

Volume

0.34M

Analyst Target

USD 81.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.28 (-0.24%)

USD 200.50B
MDT Medtronic PLC

-0.86 (-1.05%)

USD 103.90B
ZBH Zimmer Biomet Holdings Inc

-0.38 (-0.35%)

USD 21.51B
STE STERIS plc

-0.74 (-0.35%)

USD 21.31B
GMED Globus Medical

-0.86 (-1.02%)

USD 11.25B
SNN Smith & Nephew SNATS Inc

+0.33 (+1.35%)

USD 10.75B
PEN Penumbra Inc

-0.69 (-0.29%)

USD 9.31B
BIO Bio-Rad Laboratories Inc

-0.52 (-0.16%)

USD 9.17B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.16B
GKOS Glaukos Corp

-1.51 (-0.99%)

USD 8.32B

ETFs Containing INSP

PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.61 (-1.33%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.05% 39% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.05% 39% F 18% F
Trailing 12 Months  
Capital Gain -7.23% 39% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.23% 39% F 18% F
Trailing 5 Years  
Capital Gain 154.74% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 154.74% 92% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 32.44% 84% B 88% B+
Dividend Return 32.44% 84% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 71.47% 23% F 12% F
Risk Adjusted Return 45.38% 81% B- 60% D-
Market Capitalization 5.63B 63% D 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.